INMUNE BIO INC. - COMMON STOCK

INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update

03 Nov 2021 16:15:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting

27 Oct 2021 09:00:02 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3

25 Oct 2021 09:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series

27 Sep 2021 16:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences

20 Sep 2021 16:00:00 By Nasdaq GlobeNewswire

Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evidence of Remyelination

01 Sep 2021 16:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune™, Successfully Produced Memory-Like NK Cells

25 Aug 2021 16:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference

10 Aug 2021 09:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Present at the BTIG Virtual Biotechnology Conference

05 Aug 2021 08:15:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update

04 Aug 2021 16:20:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4

28 Jul 2021 16:05:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New Phase 1b AD Biomarker Data

26 Jul 2021 08:30:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer’s Association International Conference 2021

19 Jul 2021 08:30:00 By Nasdaq GlobeNewswire

INMUNE BIO, INC. ANNOUNCES $40 MILLION REGISTERED DIRECT OFFERING

14 Jul 2021 09:02:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)

12 Jul 2021 08:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution

14 Jun 2021 16:01:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN

02 Jun 2021 09:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021

24 May 2021 09:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update

05 May 2021 16:15:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5

28 Apr 2021 09:00:01 By Nasdaq GlobeNewswire